KCR shifts head office from Warsaw to Berlin to get closer to clients

By Zachary Brennan contact

- Last updated on GMT

A photo of the new headquarters in Berlin
A photo of the new headquarters in Berlin

Related tags: Europe, Eastern europe, European union

With operations across 19 European countries as well as the US, contract Research Organization KCR recently relocated its head office from Warsaw, Poland, to Berlin, Germany to be closer to clients.

The head office in Berlin will serve as a management and business development center, whereas the office in Warsaw will continue to be the company’s operational hub. KCR European coverage includes entities in Austria, France and the UK​ as well as in Central and Eastern Europe (CEE) and the Commonwealth of Independent States (CIS). The company also recently expanded into the Ukraine via the acquisition of CRO Axis​. 

Mike Jagielski​, President & CEO of KCR, said in a statement: “The establishment of a new head office in Berlin builds upon our previous decisions on strengthening the company’s footprint in Western Europe. Moving to Germany is a response to our clients’ expectations regarding KCR’s strong presence in Western Europe. It will also allow us to further diversify the KCR talent pool to support our customer focused approach​.”

Related news

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more